Health-Related Quality of Life in patients with hepatitis C in double and triple therapy

Abstract

OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

“…When assessing HRQoL, IFN-free regimens are clearly superior when compared to regimens containing IFNs. Fagundes et al demonstrated that HRQoL indices are significantly compromised during antiviral therapy with pegylated IFN and the first-generation protease inhibitors telaprevir and boceprevir but that there was a significant improvement of HRQoL after SVR [ 6 ]. Regarding HRQoL, therapy with DAAs is clearly superior to therapy based on IFN [ 15 , 22 , 23 ].…”

“…Interferon (IFN)-based treatments have been shown to be associated with impairment of quality of life indices during therapy [ 6 ]. The introduction of direct-acting antiviral (DAA) drugs has revolutionized chronic hepatitis C treatment, as they are drugs with few adverse events and a high rate of sustained virological response (SVR) [ 7 – 9 ].…”

Novos Medicamentos Para a Hepatite C: Caracterização Dos Usuários E Resultados Terapêuticos

“…Os novos fármacos Antivirais de Ação Direta (AAD), de primeira e segunda geração, revolucionaram o tratamento para a hepatite C. Os tratamentos anteriores, primeiramente com interferon, ribavirina e interferon peguilado e, mais recentemente, com boceprevir e telaprevir, possuíam, de maneira geral, inconvenientes, a exemplo da falha em mostrar atividade pangenotípica, via de administração injetável, baixa resposta virológica sustentada (RVS), longo período de aplicação para produzir efeito terapêutico (48 semanas ou mais), efeitos colaterais sistêmicos e frequentes recidivas, os quais prejudicavam a aceitabilidade da terapia pelos pacientes, além do baixo índice de cura -todos relacionados a esses fármacos antigos (1,7,9,13).…”

Factores asociados a la calidad de vida relacionada a la salud en pacientes con hepatitis C crónica en un hospital de referencia de la ciudad de Lima durante los años 2017 – 2018

“…Se ha demostrado que el régimen de tratamiento antiviral con interferón genera mayor disminución de la CVRS en comparación con un régimen libre de interferón. (10)(11)(12)(13)(14) Asimismo, un estudio colombiano determinó que los factores asociados a mala CVRS son el sexo femenino, la edad avanzada y la presencia de cirrosis hepática. (7) No obstante, no se encontró estudios en el Perú con información que precise la CVRS en pacientes con hepatitis C crónica, ni sus factores asociados.…”